Heatwurx (NASDAQ:PCSA – Get Free Report) and ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, profitability, analyst recommendations, risk and valuation.
Insider & Institutional Ownership
91.9% of Heatwurx shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 2.4% of Heatwurx shares are owned by company insiders. Comparatively, 33.5% of ARS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Heatwurx and ARS Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Heatwurx | 0 | 0 | 1 | 0 | 3.00 |
| ARS Pharmaceuticals | 0 | 0 | 5 | 1 | 3.17 |
Valuation and Earnings
This table compares Heatwurx and ARS Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Heatwurx | N/A | N/A | -$11.85 million | ($2.32) | -0.09 |
| ARS Pharmaceuticals | $89.15 million | 16.19 | $8.00 million | ($0.49) | -29.80 |
ARS Pharmaceuticals has higher revenue and earnings than Heatwurx. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Heatwurx has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.
Profitability
This table compares Heatwurx and ARS Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Heatwurx | N/A | -342.36% | -243.48% |
| ARS Pharmaceuticals | -42.74% | -21.85% | -15.88% |
Summary
ARS Pharmaceuticals beats Heatwurx on 9 of the 14 factors compared between the two stocks.
About Heatwurx
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Receive News & Ratings for Heatwurx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heatwurx and related companies with MarketBeat.com's FREE daily email newsletter.
